Gilead Sciences Inc on Friday increased enrollment target by 3,600 for a trial testing its experimental drug, remdesivir, in severe COVID-19 patients, a day after a media report said the drug was showing promise.
FILE PHOTO: A Gilead Sciences Inc. office is shown in Foster City, California, U.S. May 1, 2018. REUTERS/Stephen Lam
The enrollment estimate in the trial run by Gilead was increased to 6,000 patients from 2,400 previously, accordingBrokerage Piper Sandler said rationale for the increase was to widen access to remdesivir and to gather additional data on the drug, noting that there were no additional changes to the goals.The company has previously said it was shifting from a system of individual compassionate-use requests to expanded access programs.
But analysts and the company urged caution on drawing conclusions from the STAT report that also helped buoy the broader markets. “While the article paints a pretty picture, we think the ensuing exuberance shows a lack of critical analysis,” said Baird analyst Brian Skorney.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Why an analyst bullish on Gilead says antiviral drug ‘won’t solve’ COVID-19“Did remdesivir just ‘solve’ COVID? No,” says Umer Raffat, an analyst at Evercore ISI.
Read more »
Gupta: Federal guidance, Singapore-developed tech needed to fight COVID-19“What we need is creative thinking,' VinGuptaMD says of U.S. issues with testing for COVID-19. 'There are ways to get around these bottlenecks, we just have to have federal guidance.”
Read more »
A desperate scramble as COVID-19 families vie for access to plasma therapyEven as efforts ramp up to collect blood plasma from the first survivors of coronavirus, chances of procuring treatment appear to depend on geography, social-media savvy, and the willingness of physicians.
Read more »
A New Frontier for Self-Love—And Sex Toys—in the Time of COVID-19With an uptick in conversation around female desire and a boom in female-led sex tech companies, one Vogue writer explores self-love in the time of COVID-19.
Read more »